AEON Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-323.95	-323.95	-52.56	-55.64
Depreciation & Amortization	0.05	0.05	0.07	0
Share-Based Compensation	3.77	3.77	5.89	5.22
Other Operating Activities	294.06	294.06	11.01	21.98
Operating Cash Flow	-26.08	-26.08	-35.58	-28.43
Capital Expenditures	0	0	-0.31	-0.17
Investing Cash Flow	0	0	-0.31	-0.17
Debt Issued / Paid	0	0	40.51	15
Other Financing Activities	-	-	-	-1.44
Financing Cash Flow	0	0	40.51	13.56
Net Cash Flow	-26.08	-26.08	4.62	-15.04
Free Cash Flow	-26.08	-26.08	-35.89	-28.6
Free Cash Flow Per Share	-0.70	-0.70	-0.26	-0.23

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).